title: [Schisandrin B prevents doxorubicin-induced cardiotoxicity in rabbits].
abstract: OBJECTIVE
  To study the effect of dexrazoxane in preventing doxorubicin-induced cardiotoxicity in rabbit-models and its mechanism.
  
  
  METHODS
  Thirty one New Zealand white rabbits were randomly divided into two groups, doxorubicin (DOX) group and doxorubicin + dexrazoxane group. The cardiotoxicity was assessed by measuring serum superoxide dismutase (SOD), malondialdehyde (MDA), cardiac troponin I (cTnI), brain natriuretic peptide (BNP), left ventricular ejection function (LVEF), and left ventricular fractional shortening (LVFS), before and 4 and 10 weeks after intervention. Pathological changes in cardiac tissues and the apoptosis of myocardial cells were examined at the end of the experiment. Results Doxorubicin increased serum MDA, cTnI and BNP and decreased SOD, LVEF and LVFS (P < 0.05). Dexrazoxane (DEX) inhibited the increase of MDA, cTnI and BNP, and the decrease of LVEF and LVFS (P < 0.05). The rabbits treated with doxorubicin + dexrazoxane had slighter pathological changes in myocardium and apoptotic myocardial cells than those treated with DOX.
  
  
  CONCLUSIONS
  Dexrazoxane prevents doxorubicin-induced cardiotoxicity through decreasing oxygen free radical production, cutting down lipid peroxidation, and depressing cardiocyte apoptosis.
authors.affiliation: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Fei-Fei
authors.initials: FF
authors.lastname: Che
authors.forename: Yu
authors.initials: Y
authors.lastname: Liu
authors.forename: Cai-Gang
authors.initials: CG
authors.lastname: Xu
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000517:prevention & control*; D034242:Cyclooctanes / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000633:toxicity*; D005260:Female; D017705:Lignans / Q000494:pharmacology / Q000627:therapeutic use*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011083:Polycyclic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D011897:Random Allocation; D017382:Reactive Oxygen Species / Q000097:blood; D029633:Schisandraceae / Q000737:chemistry; D013482:Superoxide Dismutase / Q000097:blood; D019210:Troponin I / Q000097:blood
chemical_list: D034242:Cyclooctanes; D017705:Lignans; D011083:Polycyclic Compounds; D017382:Reactive Oxygen Species; D019210:Troponin I; C015499:schizandrin B; D020097:Natriuretic Peptide, Brain; D004317:Doxorubicin; D013482:Superoxide Dismutase